Lifeline Scientific, Inc Update on Retrospective Kidney Transplant Study

TIDMLSI

Lifeline Scientific, Inc

24 February 2014

24 February 2014

Lifeline Scientific, Inc.

("Lifeline" or the "Company")

Retrospective Study of all Kidney Transplants in the US Between 2000 and 2011 supports Lifeline Scientific

Lifeline Scientific (AIM: LSI: LSIC:), the transplantation technology company that manufactures the LifePort Kidney Transporter (LifePort), welcomes the publication of the 15 January edition of Transplantation (1) . In the study, 94,709 renal transplants in the USA between 2000 and 2011 were analysed with respect to delayed graft function ('DGF'), after pulsatile perfusion (PP), and also DGF after cold static storage at varying cold ischemic times ('CIT') with different donor groups. DGF is known to adversely impact near and long term graft performance and survival rates. (2.3.4)

When stratified by donor type and CIT, the adjusted odds of DGF were lower for all cold ischemic times in standard criteria donors ('SCD') transplants. The adjusted odds of DGF were lower with perfusion when CIT was greater than 6 hours in expanded criteria donors ('ECD') transplants. When CIT was between 6 and 24 hours in donors after circulatory death ('DCD') transplants, CIT was independently associated with a greater risk of DGF irrespective of storage method, but this effect was substantially modified by using machine perfusion.

The conclusion of the paper was that perfusion is associated with a reduced risk of DGF irrespective of donor type and CIT. Although PP modifies the impact of CIT on the risk of DGF, it does not eliminate its association with DGF, suggesting the optimal strategy to reduce DGF is to minimize CIT and utilize PP in all deceased donor transplants.

David Kravitz, CEO of Lifeline commented: "This retrospective study of close to 95,000 patients adds to the already significant body of evidence in the medical literature that machine perfusion leads to improved patient outcomes by reducing delayed graft function across all types of deceased donor kidneys. This study also supports findings published in the New England Journal of Medicine in 2009 from the landmark European Machine Perfusion Trial (MPT), the first ever prospective, randomized, statistically powered, multi-centre study that compared machine perfusion to cold static storage. Both studies clearly demonstrate the utility of active preservation. As clinician awareness of this evidence grows, machine perfusion is gaining momentum as a clinical standard of care. This was our dream when developing LifePort, which has now become the market leading machine preservation system worldwide. Clinicians have found that organ viability is better maintained with LifePort, thereby helping to improve post transplant outcomes and make more organs available to satisfy the increasing demand for transplantable kidneys. "

References:

1. Gill J et al, Transplantation. 2014 97(1)

2. Jochmans I et al. Ann Surg 2010; 252(5): 756-764.

3. Daly PJA et al. BJU Int 2005; 96(4): 498-501.

4. Koning OHJ et al. Transplantation 1997; 63(11): 1620-1628.

For further information:

 
 Lifeline Scientific, Inc.     www.lifeline-scientific.com 
 David Kravitz, CEO                   Tel: [phone] 
 Lisa Kieres, CFO                     Tel: [phone] 
 
 Panmure Gordon (UK) Limited      Tel: [phone] 
 Freddy Crossley/Fred Walsh 
  (Corporate Finance) 
 Adam Pollock (Corporate 
  Broking) 
 
 Walbrook                         Tel: [phone] 
                                or [e-mail] 
 Paul McManus                     Mob: [phone] 
 Mike Wort                        Mob: [phone] 
 

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products and services that improve transplant outcomes and lower the overall costs of transplantation. Its lead product is the market-leading and clinically validated LifePort Kidney Transporter. Devices for preservation of the liver, pancreas, heart and lung are in late stage pre-clinical development. Also visit: www.organ-recovery.com.

About LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to provide improved kidney preservation, evaluation and transport prior to transplantation. LifePort is the world's leading machine preservation device for kidneys. Employed by surgeons in over 160 transplant programmes in 27 countries worldwide, LifePorts have successfully preserved over 47,000 kidneys indicated for clinical transplant. The product provides a sealed, sterile, protected environment where a solution is gently pumped through the kidney at cold temperatures to minimise damage while the organ is outside the body. LifePort is lightweight and portable, allowing organs to be perfused from the time of donor recovery until recipient transplantation. It is designed to travel unaccompanied by land or air, safely transporting the kidneys across town or between countries. While the kidney is being perfused, LifePort records data on temperature, flow rate, vascular resistance and pressure every 10 seconds, providing surgeons with additional data prior to transplant. LifePort is the only system with clinical outcomes data produced from an independent, prospective, randomised, statistically powered, multi-centre clinical trial. Study results have been widely published in scientific journals, including the New England Journal of Medicine. Data indicates that patients receiving LifePort preserved kidneys experienced significant reduction in the incidence and duration of delayed graft function and increased graft survival at 1-year and 3-years post-transplant. LifePort has also been recognised for design and engineering distinctions. It has received prominent awards for design excellence from the medical device industry, has been selected for exhibition at the Smithsonian Cooper-Hewitt National Design Museum and is part of the permanent Collection of The Museum of Modern Art (MoMA) in New York City.

Lifeline Scientific, Inc. Stock

As a US Company on the Aim exchange, Lifeline Scientific, Inc. (AIM: LSI, LSIC) trades under two lines of stock. While affiliates of the Company are required to hold restricted (RegS) shares, all others may hold restricted or unrestricted. Unrestricted shares may be electronically traded through the CREST system. Both lines of stock have identical rights, preferences and privileges. Non-affiliates may transfer restricted shares to the unrestricted line after purchase through the Company's registrar. Total shares outstanding for the Company at this time are 19,446,959.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRABRGDDLSDBGSX